S&P 500   0.63 (+2.44%)
DOW   0.63 (+2.44%)
BA   187.94 (+4.43%)
S&P 500   0.63 (+2.44%)
DOW   0.63 (+2.44%)
BA   187.94 (+4.43%)
S&P 500   0.63 (+2.44%)
DOW   0.63 (+2.44%)
BA   187.94 (+4.43%)
S&P 500   0.63 (+2.44%)
DOW   0.63 (+2.44%)
BA   187.94 (+4.43%)
Log in

NASDAQ:ARQLArQule Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$20.00
0.00 (0.00 %)
(As of 01/16/2020)
Add
Compare
Today's Range
$20.00
Now: $20.00
$20.00
50-Day Range
$20.00
MA: $20.00
$20.00
52-Week Range
$3.15
Now: $20.00
$20.45
VolumeN/A
Average Volume5.27 million shs
Market Capitalization$2.42 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.49
ArQule, Inc., a biopharmaceutical company, researches and develops therapeutics for the treatment of cancer and rare diseases in the United States. The company's pipeline includes ARQ 531, an orally bioavailable, potent and reversible dual inhibitor of wild type and C481S-mutant Bruton's tyrosine kinase that is in Phase I trial for patients with B-cell malignancies refractory to other therapeutic options; and miransertib (ARQ 092), a potent and selective inhibitor of the protein kinase B (AKT), a serine/threonine kinase, which is in Phase Ib in combination with the hormonal therapy and anastrozole in patients with advanced endometrial cancer. Its pipeline also comprises ARQ 75, a potent and selective inhibitor of AKT that is in Phase I clinical development for solid tumors harboring AKT, phosphoinositide 3-kinase or phosphatase, and tensin homolog loss mutations. In addition, the company's pipeline includes Derazantinib (ARQ 087), a multi-kinase inhibitor designed to preferentially inhibit the fibroblast growth factor receptor (FGFR) family of kinases that is in a registrational clinical trial in intrahepatic cholangiocarcinoma in patients with FGFR2 fusions. ArQule, Inc. has license agreements with Basilea Pharmaceutica Limited and Roivant Sciences Ltd. The company was founded in 1993 and is headquartered in Burlington, Massachusetts.
Read More
ArQule logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.1Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.93 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:ARQL
CUSIP04269E10
Phone781-994-0300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$25.76 million
Book Value$0.72 per share

Profitability

Net Income$-15,480,000.00
Net Margins-805.61%

Miscellaneous

Employees36
Market Cap$2.42 billion
Next Earnings DateN/A
OptionableOptionable

Receive ARQL News and Ratings via Email

Sign-up to receive the latest news and ratings for ARQL and its competitors with MarketBeat's FREE daily newsletter.

ArQule (NASDAQ:ARQL) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of ArQule?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ArQule in the last year. There are currently 6 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for ArQule.

How were ArQule's earnings last quarter?

ArQule, Inc. (NASDAQ:ARQL) issued its quarterly earnings data on Wednesday, October, 30th. The biotechnology company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.08) by $0.01. The biotechnology company earned $0.21 million during the quarter, compared to analyst estimates of $1.20 million. ArQule had a negative return on equity of 33.10% and a negative net margin of 805.61%. During the same quarter last year, the firm earned ($0.05) EPS. View ArQule's earnings history.

What price target have analysts set for ARQL?

7 Wall Street analysts have issued twelve-month price objectives for ArQule's shares. Their forecasts range from $17.00 to $20.00. On average, they expect ArQule's stock price to reach $19.17 in the next year. This suggests that the stock has a possible downside of 4.2%. View analysts' price targets for ArQule.

What are Wall Street analysts saying about ArQule stock?

Here are some recent quotes from research analysts about ArQule stock:
  • 1. According to Zacks Investment Research, "ArQule, Inc. is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Company's targeted, broad-spectrum products and research programs are focused on key biological processes that are central to cancer. ArQule's lead clinical-stage products have been generated from two scientific platforms: Cancer Survival Protein modulation and Activated Checkpoint Therapy. The Cancer Survival Protein modulation platform has generated a clinical-stage product that mediates its effects by inhibiting the activity of a molecule known as c-Met, which plays multiple roles in cancer cell growth, survival, invasion, angiogenesis and metastasis. The ACT platform is designed to kill cancer cells selectively while sparing normal cells through direct activation of DNA damage response/checkpoint pathways. The Company's lead ACT program, based on the E2F-1 pathway, is partnered with Roche. " (10/31/2019)
  • 2. HC Wainwright analysts commented, "We are initiating coverage with a Buy rating and $13 price target. ArQule is a development stage biotech company that is developing four novel oral products, three for oncology indications and one for rare overgrowth diseases. Our price target is based on two of the drugs in the company’s pipeline, specifically ARQ 531 for B-cell malignancies and miransertib for rare tissue overgrowth diseases. Registrational trials for these two drugs are expected to begin in 2H19. We believe these trials will drive more interest in ArQule and push the stock higher. For the other two products, ARQ 751 and derazantinib, we consider them free call options. Management projects cash and marketable securities on the balance sheet will total approximately $160M at the end of 2019, which is forecast to fund operating expenses into 2022. Targeting treatment resistance in B-cell malignancies." (9/16/2019)

Has ArQule been receiving favorable news coverage?

News articles about ARQL stock have trended extremely negative recently, according to InfoTrie. The research group identifies positive and negative news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. ArQule earned a coverage optimism score of -4.3 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 3.0 out of 10, meaning that recent news coverage is unlikely to have an effect on the company's share price in the near future. View the latest news about ArQule.

Who are some of ArQule's key competitors?

What other stocks do shareholders of ArQule own?

Who are ArQule's key executives?

ArQule's management team includes the following people:
  • Mr. Paolo Pucci, CEO & Director (Age 58)
  • Mr. Peter S. Lawrence J.D., Pres, COO, Gen. Counsel & Sec. (Age 56)
  • Dr. Brian Schwartz, Chief Medical Officer & Sr. VP (Age 57)
  • Mr. Robert J. Weiskopf, CFO, Sr. VP, Principal Accounting Officer & Treasurer (Age 68)
  • Dr. Marc Schegerin M.D., CFO, Head of Strategy & Treasurer

What is ArQule's stock symbol?

ArQule trades on the NASDAQ under the ticker symbol "ARQL."

What is ArQule's stock price today?

One share of ARQL stock can currently be purchased for approximately $20.00.

How big of a company is ArQule?

ArQule has a market capitalization of $2.42 billion and generates $25.76 million in revenue each year. The biotechnology company earns $-15,480,000.00 in net income (profit) each year or ($0.16) on an earnings per share basis. ArQule employs 36 workers across the globe.

What is ArQule's official website?

The official website for ArQule is www.arqule.com.

How can I contact ArQule?

ArQule's mailing address is ONE WALL STREET, BURLINGTON MA, 01803. The biotechnology company can be reached via phone at 781-994-0300 or via email at [email protected]

This page was last updated on 7/15/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.